<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145767</url>
  </required_header>
  <id_info>
    <org_study_id>PRMT15</org_study_id>
    <nct_id>NCT02145767</nct_id>
  </id_info>
  <brief_title>Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial</brief_title>
  <official_title>Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Miscarriages and preterm births are common and serious events affecting women, families, and&#xD;
      healthcare systems on many levels. One of the risk factors for miscarriage and preterm birth&#xD;
      is bleeding in the first trimester of pregnancy. Progesterone, a hormone that plays a key&#xD;
      role during pregnancy, has been proposed as a possible medication to be used in pregnancy to&#xD;
      prevent miscarriage and preterm birth among women who have bleeding in their first trimester&#xD;
      of pregnancy. Unfortunately, unless sound clinical evidence is obtained through a clinical&#xD;
      trial, whether or not progesterone can indeed prevent miscarriage and preterm birth remains&#xD;
      uncertain and thus is not a recommended treatment in women with early pregnancy bleeding. The&#xD;
      purpose of our study is to evaluate the effect of progesterone for the prevention of&#xD;
      miscarriage and preterm birth among women with early pregnancy bleeding. We will carry out a&#xD;
      clinical trial in which 850 women will be randomized to receive either progesterone&#xD;
      supplementation (425 women) or a similarly appearing placebo (425 women) and the outcome of&#xD;
      their pregnancy will be compared.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">February 2021</completion_date>
  <primary_completion_date type="Actual">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Miscarriage</measure>
    <time_frame>From 6-8 weeks of pregnancy until miscarriage</time_frame>
    <description>Occurrence of a miscarriage (&lt;20 weeks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preterm birth</measure>
    <time_frame>From 6-8 weeks of pregnancy until delivery</time_frame>
    <description>Occurrence of preterm birth (&lt;37 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal outcomes</measure>
    <time_frame>From 6-8 weeks of pregnancy until 6 weeks post delivery</time_frame>
    <description>Antenatal admissions, treatment of preterm labor etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal outcomes</measure>
    <time_frame>2 days to 6 weeks post delivery</time_frame>
    <description>Malformations, growth restriction, prematurity associated morbidity, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare outcomes</measure>
    <time_frame>From 6-8 weeks of pregnancy until 6 weeks post delivery</time_frame>
    <description>Hospital costs, etc</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Miscarriage</condition>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progesterone 200mg suppository administered vaginally at bedtime until 34 completed weeks of pregnancy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Similar appearing suppository containing vehicle alone administered vaginally at bedtime until 34 completed weeks of pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <arm_group_label>Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Live intrauterine singleton pregnancy of &lt;14 weeks by crown-rump length on ultrasound&#xD;
             with documented fetal cardiac activity&#xD;
&#xD;
          -  Presence of a perigestational (subchorionic) hemorrhage on ultrasound&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to Progesterone&#xD;
&#xD;
          -  Any indication for progesterone&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haim Abenhaim, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karma Medical Clinic</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2H 5Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUHC Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Haim Abenhaim</investigator_full_name>
    <investigator_title>Obstetrician &amp; Gynecologist, Maternal Fetal Medicine Specialist, Director of Perinatal Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

